Nov 02, 2026
Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter
As of Nov. 2, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
Here’s the latest list of major overbought players in this sector.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
- On Oct. 30, Regeneron Pharmaceuticals reported better-than-expected third-quarter financial results. “We are pleased with our third quarter financial results, which marked our third consecutive quarter of double-digit growth in both revenue and non-GAAP EPS,” said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron. The company’s stock gained around 22% over the past month and has a 52-week high of $935.35.
- RSI Value: 78.9
- REGN Price Action: Shares of Regeneron Pharmaceuticals rose 13.3% to close at $927.89 on Friday.
- Edge Stock Ratings: 83.56 Momentum score with Value at 63.02.
AstraZeneca PLC (NYSE:AZN)
- On Oct. 30, AstraZeneca reported better-than-expected third-quarter financial results. “Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars,” CEO Pascal Soriot said. The company’s stock gained around 16% over the past month and has a 52-week high of $212.71.
- RSI Value: 75
- AZN Price Action: Shares of AstraZeneca gained 7% to close at $186.65 on Friday.
Exelixis Inc (NASDAQ:EXEL)
- On Oct. 29, Exelixis reported better-than-expected third-quarter financial results. “Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. The company’s stock gained around 19% over the past month and has a 52-week high of $72.10.
- RSI Value: 81.7
- EXEL Price Action: Shares of Exelixis rose 4.8% to close at $69.39 on Friday.
Curious about other BZ Edge Rankings? Click here to discover how similar stocks measure up.
Photo via Shutterstock
